CN115125084A - 一种佳酿养生酒及其酿造方法 - Google Patents
一种佳酿养生酒及其酿造方法 Download PDFInfo
- Publication number
- CN115125084A CN115125084A CN202210761587.2A CN202210761587A CN115125084A CN 115125084 A CN115125084 A CN 115125084A CN 202210761587 A CN202210761587 A CN 202210761587A CN 115125084 A CN115125084 A CN 115125084A
- Authority
- CN
- China
- Prior art keywords
- parts
- vintage
- ganoderma lucidum
- wild
- glutinous rice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 6
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 50
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 50
- 239000000843 powder Substances 0.000 claims abstract description 27
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 20
- 235000009566 rice Nutrition 0.000 claims abstract description 20
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 17
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 16
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims abstract description 15
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 12
- 235000009434 Actinidia chinensis Nutrition 0.000 claims abstract description 9
- 244000298697 Actinidia deliciosa Species 0.000 claims abstract description 9
- 241000209094 Oryza Species 0.000 claims description 19
- 241000222336 Ganoderma Species 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 10
- 241000190633 Cordyceps Species 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 41
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 13
- 201000011510 cancer Diseases 0.000 abstract description 10
- 230000002708 enhancing effect Effects 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 11
- 150000003648 triterpenes Chemical class 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 244000298715 Actinidia chinensis Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 208000013116 chronic cough Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- UGRVYFQFDZRNMQ-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonohydrazide Chemical compound CC(C)C1=CC(C(C)C)=C(S(=O)(=O)NN)C(C(C)C)=C1 UGRVYFQFDZRNMQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010061533 Myotonia Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000003835 adenosine derivatives Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000013124 brewing process Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000210 effect on cough Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- -1 tetracosan Chemical compound 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
- C12G3/021—Preparation of other alcoholic beverages by fermentation of botanical family Poaceae, e.g. wheat, millet, sorghum, barley, rye, or corn
- C12G3/022—Preparation of other alcoholic beverages by fermentation of botanical family Poaceae, e.g. wheat, millet, sorghum, barley, rye, or corn of botanical genus Oryza, e.g. rice
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
- C12G3/026—Preparation of other alcoholic beverages by fermentation with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides, added before or during the fermentation stage; with flavouring ingredients added before or during the fermentation stage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲8~22份、野生灵芝1~4份、孢子粉2~8份、铁皮石斛5~12份、西洋参3~8份、冬虫夏草0.1~0.6份、野生白猕猴桃根3~10份,其余为水;本产品具有具有滋补身体,提高免疫力,消除疲劳,改善血液循环能力,益肾固本,清理血液中有害垃圾,软化血管,抗肿瘤、抗癌,延缓细胞与人体的衰老,延年益寿的功效。
Description
技术领域
本发明涉及保健酒领域,具体涉及一种佳酿养生酒及其酿造方法。
背景技术
保健酒系指适用于特定人群饮用,具有调节机体功能,不以治疗为目的的酒,保健酒是以蒸馏酒、发酵酒或食用酒精为酒基,以可用植物为保健功效成分来源制备而成的一种保健食品,深受广大消费者喜欢。
市面上的保健酒五花八门,但大多数均采用以糯米、小麦、大米和除去胚芽的玉米等做原料,经过酿造并添加了一些增香调味物质来进行调和得到各种保健功效的药酒,除了酿造酒以外,市面上更多的是利用化学配方来勾兑的药酒,虽然都符合国家食品要求,但这几类酒已经完全区别于纯天然原材料进行酿制的酒以及相关功效。
发明内容
本发明要解决的技术问题是提供一种佳酿养生酒。
为解决上述问题,本发明采用如下技术方案:一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲8~22份、野生灵芝1~4份、孢子粉2~8份、铁皮石斛5~12份、西洋参3~8份、冬虫夏草0.1~0.6份、野生白猕猴桃根3~ 10份,其余为水。
进一步的,包括糯米100份、红曲12份、野生灵芝2份、孢子粉4份、铁皮石斛8份、西洋参5份、冬虫夏草0.3份、野生白猕猴桃根5份,其余为水。
进一步的,所述水按糯米和红曲总质量的1:1进行添加。
进一步的,所述水为山泉水。
一种佳酿养生酒的酿造方法,包括以下步骤:
1)、首先选用上好的糯米和红曲,把糯米放入蒸笼蒸熟后备用;2)、再将野生灵芝、铁皮石斛、西洋参、冬虫夏草、野生白猕猴桃根和孢子粉研磨成粉与山泉水混合进行搅拌;3)、搅拌完成后放入红曲进行搅拌,然后再放入蒸熟的糯米进行搅拌;4)、步骤3)搅拌完成后再进行发酵,时间为2个月;5)、发酵完成后进行蒸馏处理,蒸馏完成后倒入罐体封罐窖藏,最终得到成品佳酿养生酒。
野生灵芝:灵芝科是高等真菌的一个重要科,系世界广分布类群。野生灵芝,顾名思义,是相对人工养殖灵芝而言的,指的是森林中纯自然生长的灵芝,药王孙思邈把在林中寻得的野生灵芝称为“琼珍”,后来人们就把这种山林中的灵芝称为琼珍灵芝,古代时期皇帝称之为“仙药”。
灵芝类所含化学成分非常复杂,多数的灵芝化学成分主要有:三萜类化合物、多糖类、核苷类、甾醇类、生物碱类、呋喃衍生物、氨基酸多肽类、无机元素、脂肪酸等,三萜类化合物:三萜类化合物是灵芝的主要化学成分之一,灵芝中的很多三萜类化合物具有生理活性。1982年Kubota.T等人首次从赤芝子实体中分离得到三萜类化合物。到目前为止,已先后从赤芝子实体和孢子粉中分离了103种新的三萜类化学成分。中国科学院介入灵芝研究,经研究证实其药理作用为:三萜类化合物(尤其是四环三萜、五环三萜)是灵芝的主要药理成分,是灵芝(孢子)发挥抗炎、镇痛、毒杀肿瘤细胞、抗缺氧等作用的主要功效成分。实验证明灵芝三萜类具有迅速提高免疫力,表现在促进淋巴细胞增殖,提高巨噬细胞、NK细胞、T细胞的吞噬能力和杀伤力。并直接和间接毒杀肿瘤细胞,同时能够激活化疗药物难以杀死的Go期肿瘤细胞,进行单独或联合毒杀。二、灵芝多糖:灵芝多糖是灵芝的生物活性物质之一,多糖的研究以赤芝、紫芝居多,以日本、中国(含台湾地区)、印度尼西亚、韩国、新加坡等研究较多,发展不平衡。总的来说,多糖研究的广度、深度不如三萜类化合物。灵芝多糖类药理作用:具有抗肿瘤作用、免疫调节作用、降血糖作用、降血脂作用、抗氧化作用和抗衰老作用。三、核苷类:核苷类是由核糖和嘌呤、嘧啶等结合的化合物,也是生物的一次性代谢产物,它能溶于水,有广泛的药理活性。据文献记载,其药理作用有:能治疗进行性肌营养不良、萎缩性肌强直,抑制肌强直症小鼠的血清醛缩酶、抑制血小板凝集,有镇静剂、抗缺氧,提高心肌组织营养吸收能力等。其中灵芝中分离出来的腺苷功效最为显著,效果广泛。
灵芝与心脑血管:灵芝有“血管清道夫”的美称,清理血液、软化血管、降低血液粘度、抑制血小板聚集防止血栓形成。
灵芝与高血压:灵芝可以用于心绞痛、心肌梗塞、高血压、高血脂、高血粘症、动脉粥样硬化、年年痴呆等病症,灵芝孢子粉能维持舒张压稳定,使头痛、目眩、耳鸣症状很快消失,当血压过低时,服用灵芝孢子粉后血压升高,说明有双向调节作用。
灵芝与护肝灵芝孢子粉有显著降低转氨酶,有效减轻和防止肝损伤,减轻由于乙硫氨酸引起的脂肪肝、促进肝细胞再生、加强肝脏解毒能力、对于肝功能衰竭也有疗效。
灵芝与睡眠:灵芝孢子粉对失眠和神经衰弱有明显效果,顽固的神经衰弱者在服10-15天后能有效改善睡眠,表现为精神振奋、记忆力增强。对耳鸣、乏力:胃寒等症状也有缓解作用。
灵芝与免疫调节:灵芝孢子粉有双向调节免疫功能、增强免疫细胞和体液免疫的活性、促进艰核巨噬细胞的吞噬能力、增强清除体内异物、杀伤肿瘤细胞的能力。
灵芝与肿瘤:灵芝孢子粉在预防癌症、抗肿瘤癌症、阻止癌细胞扩散与转移等是通过提高患者免疫力实现的,癌症发生都与免疫力下降息息相关,免疫力的提高可阻止组织细胞变异,预防癌症患者猝死于血栓症,能抑制血栓的形成,瓦解组织周围的血栓壁。清除治疗药物被阻止现象,对接受化疗患者可提高对放化疗患者毒性耐受性,能消除细胞癌症特有的剧痛,减轻或消除化疗引起的白细胞减少,脱发,食欲减退呕吐等副作用,能改善恶病质,提高生存质量,延长生命。
灵芝与呼吸系统:灵芝孢子粉对慢性支气管炎的咳、痰、D岗均有一定疗效,多在服用1-2周后见效,肺动脉高压、心室肥厚等症状能够减轻或消失,服用者抗寒能力增强、减少感冒、食欲增加、对呼吸系统疾病冬季减少发作较轻。
灵芝与长寿:灵芝孢子粉有清除自由基,抑制端粒酶活性的作用,提高SOD 活性水平、增加白细胞介素11-2的产生,增强锌与硫醇基的结合,延缓细胞与人体的衰老、因而有美容养颜、抗衰老的功效。
孢子粉:孢子粉是灵芝发育后期弹射释放出来的种子,生物学上称为担孢子,集中起来后呈粉末状,孢子内含有比灵芝更丰富的多糖肽、腺嘌呤核苷、蛋白质、酶、三萜类、有机锗、微量元素等特殊成份,除含有三铁、多糖类等成分外,还含有胆碱、二十四烷、棕榈酸、三十一烷、β-古甾醇等多种有效成分,此外,还含有丰富的氨基酸、脂肪酸、维生素、微量元素等成分。灵芝孢子对人完全没有毒性,是一种安全可靠的保健食品,破壁率98%以上。抑制肿瘤、宁心安神、降压降糖、促进睡眠、健脾开胃、养颜美容、延年益寿、消除疲劳、提高人体免疫能力、具有扶正固本的功效,灵芝粗多糖,灵芝粗多糖有广泛的药理活性,能提供机体免疫力,提高机体耐氧能力,消除自由基,抗放射,解毒,提高肝脏、骨髓、血液合成DHA、RHA、蛋白质能力,延长寿命,抑制肿瘤等功效,灵芝酸是孢子粉的主要功效成份之一,具有强烈的药理活性,并有止痛、镇静、抑制组织胺释放、解毒、保肝、毒杀肿瘤细胞等功能,灵芝孢子粉含有多种腺苷衍生物。腺苷衍生物能抑制血小板的过度聚集能力,对老年瘀血者具有良好的解血凝能力,从而能改善人体血液循环,防止血栓病如:脑血栓、心肌梗塞、血流不畅、机体无力等疾病,孢子粉中赤芝孢子内酯A:具有降胆固醇作用;赤芝孢子酸A:具有降转氨酶作用;灵芝碱甲、灵芝碱乙:具有抗炎症作用;尿嘧啶和尿嘧啶核苷:能降低实验性肌强直症小鼠血清醛缩酶;腺嘌呤核苷:具有镇静、抗缺氧等作用;腺嘌呤:具有镇静、降血清胆固醇,抗缺氧等作用;油酸:抗过敏作用;灵芝总碱:明显增加冠脉血流量,降低冠脉阻力及降低心肌耗氧量,提高心肌对氧的利用率,改善缺血性心电图变化;增加冠脉流量和脑血流量,还能明显减轻冠状动脉左旋支诱发的急性实验性心肌梗塞;灵芝孢子中的孢醚,可使肝脏再生能力增强;灵芝孢子纤维素:具有降胆固醇,预防动脉粥样硬化,治疗便秘、糖尿病、高血压、脑血栓等疾病。
铁皮石斛:铁皮石斛是兰科草本植物,生于海拔达1600米的山地半阴湿的岩石上,其茎入药,属补益药中的补阴药:益胃生津,滋阴清热,喜温暖湿润气候和半阴半阳的环境,不耐寒,1987年国务院发布的《野生药材资源保护管理条例》将铁皮石斛列为三级保护品种;其性味功效:味甘,性微寒,生津养胃;滋阴清热;润肺益肾;明目强腰,生津作用:铁皮石斛石斛具有生津作用,主要表现为促进腺体分泌和脏器运动,降血糖作用:铁皮石斛对可降低链脲霉素诱发糖尿血糖值,增强机体免疫力:铁皮石斛颗粒(TPSH)可促进荷瘤动物巨噬细胞的吞噬功能,增强T淋巴细胞的增殖和分化及NK细胞的活性,并能明显提高荷瘤动物的血清溶血素值,提示TPSH无论是对非特异性免疫功能,或是特异性细胞免疫以及体液免疫功能,均有一定的提高作用。
西洋参:西洋参是五加科、人参属多年生草本植物,西洋参是一种“清凉”参,其味苦、微甘,性凉,具有滋阴补气、生津止渴、除烦躁、清虚火、扶正气、抗疲劳的功效,西洋参中含有一种叫人参皂苷的成分,具有提高人体抵抗力的作用,因此,体质较弱的人,如老年人、身患重病的人,时常服用西洋参都能够起到一定的增强体质作用。而一些有慢性疾病的人,如患慢性乙肝的人,服用西洋参也会有利于病情的控制和好转其主要功效有:1、增强中枢神经系统功能:西洋参中的皂甙可以有效增强中枢神经,达到静心凝神、消除疲劳、增强记忆力等作用,可适用于失眠、烦躁、记忆力衰退及老年痴呆等症状;2、保护心血管系统:常服西洋参可以抗心律失常、抗心肌缺血、抗心肌氧化、强化心肌收缩能力,冠心病患者症状表现为气阴两虚、心慌气短可长期服用西洋参,疗效显著,西洋参的功效还在于可以调节血压,可有效降低暂时性和持久性血压,有助于高血压、心律失常、冠心病、急性心肌梗塞、脑血栓等疾病的恢复; 3、提高免疫力:西洋参作为补气保健首选药材,可以促进血清蛋白合成、骨髓蛋白合成、器官蛋白合成等,提高机体免疫力,抑制癌细胞生长,有效抵抗癌症;4、促进血液活力:长服西洋参可以降低血液凝固性、抑制血小板凝聚、抗动脉粥样硬化并促进红血球生长,增加血色素;5、治疗糖尿病:西洋参可以降低血糖、调节胰岛素分泌、促进糖代谢和脂肪代谢,对治疗糖尿病有一定辅助作用;⑥西洋参还可以强化心肌及增强心脏之活动能力;强壮中枢神经,安定身心并恢复疲劳,有镇静及解酒作用,增强记忆能力,对老人痴呆症有显著功效;对血压有调整作用,使暂时性或持久性血压下降,抑制动脉硬化并促进红血球生长,增加血色素的份量;能调节胰岛素分泌,因此对糖尿病有功效;对肝脏有调节副肾上腺素之分泌,促进新陈代谢的作用;能增强体力并对运动员具极大助益;抑制癌细胞生长,增加免疫功能;助长消化,对慢性胃病和肠胃衰弱有助效。
冬虫夏草:冬虫夏草,中药名。为麦角菌科虫草属真菌冬虫夏草菌寄生在蝙蝠蛾科昆虫幼虫上的子座及幼虫的尸体的复合体。具有补肾益肺,止血化痰功效。入药部位,子座及幼虫的尸体的复合体,主治腰膝酸痛、久咳虚喘、劳嗽痰血,久咳虚喘,劳嗽痰血:本品甘平,为平补肺肾之佳品,功能补肾益肺、止血化痰、止咳平喘,尤为劳嗽痰血多用。性味,甘,平,归经,归肺、肾经,功效,补肾益肺,止血化痰。药材性状:本品由虫体及从头部长出的真菌子座组成。虫体似蚕,长3-5cm,直径3-8mm,表面深棕黄色至黄棕色,有环纹20-30 个,近头部的环纹较细;头部红棕色,足8对,中部4对较明显;质脆,易折断,断面略平坦,淡黄白色。子座单生,细长圆杜形,长4-7cm,直径约3mm;求面深棕色至棕褐色,有细纵皱纹,上部稍膨大,头部与柄无明显区别;质柔韧,断面类白色。气微腥,味淡。本品含蛋白质氨基酸的游离氨基酸,其中多为人体必需氨基酸,还含有糖、维生素及钙、钾、铬、镍、锰、铁、铜、锌等元素。对中枢神经系统有镇静、抗惊厥、降温等作用,对体液免疫功能有增强作用,虫草的水或醇提取物可明显抑制小白鼠肉瘤等肿瘤的成长,虫草菌发酵液可对抗家兔心肌缺的ST段改变,虫草菌对大鼠应激性心梗也有一定的保护作用,虫草水提液对大鼠急性肾衰有明显的保护作用。相关论述:《本草从新》:“甘平保胪益肾,止血化痰,已劳嗽,《药性考》:“味甘性温,秘精益气,专补命门。
白猕猴桃根:白猕猴桃属于双子叶食物纲,是药食两用珍品,果实营养价值高,特别是维生素C含量每100g鲜果肉中含1135.1毫克,比中华猕猴桃高 2-10倍,其中钾元素的含量接近含钾丰富的香蕉,是一种营养高度集中的天然产物,猕猴头含有亮氨酸、苯丙氨酸、异亮氨酸、酪氨酸、丙氨酸等10多种氨基酸,以及丰富的矿物质,包括丰富的钠、钾、镁和氯以及色素等多种成分,还含有和多种维生素,对保持具有重要的作用。猕猴桃含有丰富的碳水化合物、膳食纤维、维生素和微量元素,尤其维生素C、维生素A、叶酸的含量较高。猕猴桃含有优良的膳食纤维和丰富的抗氧化物质,能够起到清热降火、润燥通便、增强人体免疫力的作用。猕猴桃含有抗突变成分谷胱甘肽,有利于抑制癌症基因的突变,对肝癌、肺癌、皮肤癌、前列腺癌等多种癌细胞病变有一定的抑制作用。猕猴桃富含精氨酸,能有效地改善血液流动,阻止血栓的形成,对降低冠心病、高血压、心肌梗塞、动脉硬化等心血管疾病的发病率和治疗阳痿有特别功效
本发明的有益效果是:
本产品采用纯天然原材料酿制,通过特殊工艺加工蒸制以及发酵与酿酒技术酿制成佳酿养生酒,在酿酒过程中集中提取了所有原材料含有对人体有益的营养成分,制成多重效果有益成分佳酿养生酒,适当饮用本酒促使人体补充多种微量元素以及营养成分;本酒具有滋补身体,提高免疫力,消除疲劳,改善血液循环能力,益肾固本,清理血液中有害垃圾,软化血管,抗肿瘤、抗癌,延缓细胞与人体的衰老,延年益寿的功效。
具体实施方式
下面对本发明的优选实施例进行详细阐述,以使本发明的优点和特征能更易于被本领域技术人员理解,从而对本发明的保护范围做出更为清楚明确的界定。
实施例一
一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲12份、野生灵芝2份、孢子粉4份、铁皮石斛8份、西洋参5份、冬虫夏草0.3份、野生白猕猴桃根5份,其余为水,其中,份的单位可以为斤或者公斤。
实施例二
一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲8份、野生灵芝1份、孢子粉2份、铁皮石斛5份、西洋参3份、冬虫夏草0.1份、野生白猕猴桃根3份,其余为水。
实施例三
一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲22份、野生灵芝4份、孢子粉8份、铁皮石斛12份、西洋参8份、冬虫夏草0.6份、野生白猕猴桃根10份,其余为水。
实施例四
一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲15份、野生灵芝3份、孢子粉6份、铁皮石斛5份、西洋参3份、冬虫夏草0.5份、野生白猕猴桃根10份,其余为水。
实施例五
一种佳酿养生酒,包括以下重量比成分:糯米100份、红曲20份、野生灵芝3份、孢子粉6份、铁皮石斛10份、西洋参6份、冬虫夏草0.3份、野生白猕猴桃根8份,其余为水。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何不经过创造性劳动想到的变化或替换,都应涵盖在本实用新保护范围为准。
Claims (5)
1.一种佳酿养生酒,其特征在于:包括以下重量比成分:糯米100份、红曲8~22份、野生灵芝1~4份、孢子粉2~8份、铁皮石斛5~12份、西洋参3~8份、冬虫夏草0.1~0.6份、野生白猕猴桃根3~10份,其余为水。
2.根据权利要求1所述的一种佳酿养生酒,其特征在于:包括以下重量比:糯米100份、红曲12份、野生灵芝2份、孢子粉4份、铁皮石斛8份、西洋参5份、冬虫夏草0.3份、野生白猕猴桃根5份,其余为水。
3.根据权利要求1所述的一种佳酿养生酒,其特征在于:所述水按糯米和红曲总质量的1:1进行添加。
4.根据权利要求1所述的一种佳酿养生酒,其特征在于:所述水为山泉水。
5.根据权利要求1所述的一种佳酿养生酒的酿造方法,其特征在于:
1)、首先选用上好的糯米和红曲,把糯米放入蒸笼蒸熟后备用;
2)、再将野生灵芝、铁皮石斛、西洋参、冬虫夏草、野生白猕猴桃根和孢子粉研磨成粉与山泉水混合进行搅拌;
3)、搅拌完成后放入红曲进行搅拌,然后再放入蒸熟的糯米进行搅拌;
4)、步骤3)搅拌完成后再进行发酵,时间为2个月;
5)、发酵完成后进行蒸馏处理,蒸馏完成后倒入罐体封罐窖藏,最终得到成品佳酿养生酒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210761587.2A CN115125084A (zh) | 2022-06-30 | 2022-06-30 | 一种佳酿养生酒及其酿造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210761587.2A CN115125084A (zh) | 2022-06-30 | 2022-06-30 | 一种佳酿养生酒及其酿造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115125084A true CN115125084A (zh) | 2022-09-30 |
Family
ID=83382722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210761587.2A Pending CN115125084A (zh) | 2022-06-30 | 2022-06-30 | 一种佳酿养生酒及其酿造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115125084A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1254005A (zh) * | 1999-08-07 | 2000-05-24 | 林金儿 | 酒中酒的酿制方法及其制品 |
CN103571685A (zh) * | 2013-10-10 | 2014-02-12 | 浙江农林大学 | 一种铁皮石斛红曲酒及其酿造方法 |
CN105349323A (zh) * | 2015-12-03 | 2016-02-24 | 贵州谊强红曲酒业有限公司 | 复合型红曲酒及其酿造方法 |
CN108034545A (zh) * | 2017-12-28 | 2018-05-15 | 曹隆君 | 一种发酵酒的制备工艺 |
CN108570387A (zh) * | 2018-07-30 | 2018-09-25 | 莫英 | 一种糯米酒的制作方法 |
-
2022
- 2022-06-30 CN CN202210761587.2A patent/CN115125084A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1254005A (zh) * | 1999-08-07 | 2000-05-24 | 林金儿 | 酒中酒的酿制方法及其制品 |
CN103571685A (zh) * | 2013-10-10 | 2014-02-12 | 浙江农林大学 | 一种铁皮石斛红曲酒及其酿造方法 |
CN105349323A (zh) * | 2015-12-03 | 2016-02-24 | 贵州谊强红曲酒业有限公司 | 复合型红曲酒及其酿造方法 |
CN108034545A (zh) * | 2017-12-28 | 2018-05-15 | 曹隆君 | 一种发酵酒的制备工艺 |
CN108570387A (zh) * | 2018-07-30 | 2018-09-25 | 莫英 | 一种糯米酒的制作方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102669772B (zh) | 中草药益胃保健饮品 | |
CN101006817A (zh) | 一种竹叶茶及其生产方法 | |
CN101416671A (zh) | 一种保健清火茶 | |
CN102965235B (zh) | 一种板栗养生酒 | |
CN106244371B (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
CN100500014C (zh) | 一种保健茶 | |
CN106615431A (zh) | 一种菊芋片茶及其制作方法 | |
CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
CN110897147A (zh) | 铁皮石斛解酒保肝组合物和制法 | |
CN101467582A (zh) | 九制益寿茶 | |
CN103461585B (zh) | 补气养生中药茶 | |
CN109395028A (zh) | 一种预防、治疗三高症的葛景甲参酒配方及制备方法 | |
CN109170888A (zh) | 一种抗氧化、抗疲劳组合物及其制备方法 | |
CN103725467B (zh) | 一种高丽参红葡萄酒的制备方法 | |
CN103082240B (zh) | 一种胡萝卜参的加工方法 | |
CN108041391A (zh) | 一种黑人参茶氨酸饮品及其制备方法 | |
CN106924548A (zh) | 一种缓解疲劳的药物及制备方法 | |
CN107519310A (zh) | 提高精力抑制肿瘤细胞生长功能的中药组合物和制备工艺 | |
CN105410243A (zh) | 一种四季养生保健茶 | |
CN115125084A (zh) | 一种佳酿养生酒及其酿造方法 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
CN102028718A (zh) | 一种解酒毒的药物及其制备方法 | |
CN104305433A (zh) | 一种红枣茶菌饮料及其制备方法 | |
CN102827731B (zh) | 保健酒的制备工艺 | |
CN105361149A (zh) | 一种青稞虫草糁子营养粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220930 |